Session » (2377–2436) Systemic Lupus Erythematosus – Diagnosis, Manifestations, & Outcomes Poster III

Date: Tuesday, October 28, 2025

Time: 10:30AM-12:30PM

Meeting: ACR Convergence 2025

10:30AM-12:30PM: Abstract Number: 2389

A Comparison of Patients with Older Onset vs. Younger Onset SLE: A Retrospective Cohort Study

10:30AM-12:30PM: Abstract Number: 2396

A Machine Learning Algorithm Based on a 15-Autoantibody Profile by a Novel Fully Automated Multiplexed Microarray Immunoassay for the Diagnosis of Autoimmune Connective Tissue Diseases

10:30AM-12:30PM: Abstract Number: 2395

Analysis of histopathological changes in the placenta of patients with systemic lupus erythematosus

10:30AM-12:30PM: Abstract Number: 2397

Analytical Performance of a Fully Automated Multiplexed Microarray Immunoassay for the Simultaneous Detection of Fifteen Autoantibodies Associated with Connective Tissue Diseases in a Reference Laboratory in Southern France

10:30AM-12:30PM: Abstract Number: 2398

Analytical performance of the HEp-2 substrate Diagnostic Kit for ANA as an initial step in the evaluation of a novel Fully Automated IFA Analyzer in a laboratory in England

10:30AM-12:30PM: Abstract Number: 2417

Anti-dense fine speckled 70 antibodies in undefined disease, systemic autoimmune rheumatic diseases and controls

10:30AM-12:30PM: Abstract Number: 2386

Anti-Trim72 Auto-antibodies In Systemic Lupus Erythematosus Patients and a Lupus Mouse Model with Myocarditis Compromise Membrane Repair in Mouse & Human Cardiomyocytes

10:30AM-12:30PM: Abstract Number: 2391

Antinuclear Antibody Positivity in Patients with Psoriasis and Psoriatic Arthritis and the Risk of Developing Clinical Symptoms of SLE Following TNF Inhibitor Therapy

10:30AM-12:30PM: Abstract Number: 2401

Associations between Serum Levels of Soluble Urokinase Plasminogen Activator Receptor (suPAR) and Activity and Chronicity Features in Diagnostic and Per-Protocol Repeat Kidney Biopsies in Patients with Lupus Nephritis

10:30AM-12:30PM: Abstract Number: 2414

Autoantibody Clusters and SIGLEC1 are Predictive of Systemic Lupus Erythematosus Development

10:30AM-12:30PM: Abstract Number: 2382

Autoimmune Hemolytic Anemia in SLE: A Real-World National Cohort Study

10:30AM-12:30PM: Abstract Number: 2431

Bone marrow- activity on 18F-FDG PET/CT as a Predictor of Hematologic Manifestations in Systemic Lupus Erythematosus

10:30AM-12:30PM: Abstract Number: 2423

Clinical and Sociodemographic Factors Associated with Diagnostic Delays in Pediatric Lupus Patients

10:30AM-12:30PM: Abstract Number: 2404

Clinical features of Elderly-onset Systemic Lupus Erythematosus

10:30AM-12:30PM: Abstract Number: 2422

Cluster Analysis of Autoantibodies in Patients with Systemic Lupus Erythematosus

10:30AM-12:30PM: Abstract Number: 2388

Correlation between Activity Index, Organ Damage Index, and HAQ in Systemic Lupus Erythematosus: a single-center study

10:30AM-12:30PM: Abstract Number: 2409

Cutaneous Lupus Activity Investigator’s Global Assessment―Revised (CLA-IGA-R) Content Validity: Cutaneous Lupus Erythematosus (CLE) Patient Qualitative Study

10:30AM-12:30PM: Abstract Number: 2428

Differences in Dyspigmentation and Scarring Across Cutaneous Lupus Erythematosus Categories and Subtypes

10:30AM-12:30PM: Abstract Number: 2403

Differential Risk of Inpatient Admissions Among SLE Subgroups: A Population-Based Analysis

10:30AM-12:30PM: Abstract Number: 2416

Direct and Indirect Costs Associated with Damage Accrual: Results from the Systemic Lupus International Collaborating Clinics (SLICC) Inception Cohort

10:30AM-12:30PM: Abstract Number: 2408

Direct Medical Cost Burden of Cutaneous Lupus Erythematosus (CLE): A Comparison with Psoriasis, Atopic Dermatitis, and a General Population

10:30AM-12:30PM: Abstract Number: 2430

Disease Activity Independently Correlates with Cognitive Impairment in Systemic Lupus Erythematosus

10:30AM-12:30PM: Abstract Number: 2392

Does Obesity Influence Disease Activity and Biomarkers in Systemic Lupus Erythematosus Patients?: A Retrospective Study

10:30AM-12:30PM: Abstract Number: 2419

Dried Blood Spots for Remote ANA and Autoantibody Screening

10:30AM-12:30PM: Abstract Number: 2432

Duffy Null Genotype and Autoantibodies Synergistically Contribute to Severe Leukopenia in Systemic Lupus Erythematosus

10:30AM-12:30PM: Abstract Number: 2415

Evaluating the Readability and Comprehension of Patient Education Materials for Systemic Lupus Erythematosus (SLE) Available Online

10:30AM-12:30PM: Abstract Number: 2412

Evolving Trends in Pulmonary Arterial Hypertension among Systemic Lupus Erythematosus Patients: A Nationwide Analysis

10:30AM-12:30PM: Abstract Number: 2378

Factors Associated With Fatigue In Systemic Lupus Erythematosus: Data From The Almenara Lupus Cohort

10:30AM-12:30PM: Abstract Number: 2380

Factors Influencing Time to Diagnosis in Systemic Lupus Erythematosus: A Real-World Retrospective Analysis

10:30AM-12:30PM: Abstract Number: 2402

High-Resolution Proteomic Profiling Validates BAFF Pathway Modulation and Reveals Novel Biomarker Signatures in Belimumab Treatment

10:30AM-12:30PM: Abstract Number: 2413

Hydroxychloroquine and Adverse Cardiovascular Outcomes in Pregnant Patients with Systemic Lupus Erythematosus

10:30AM-12:30PM: Abstract Number: 2399

Identification of an LN endotype linked to intestinal expansion of Pathogenic Strains of a Pathobiont Bacterium that induces Systemic Thrombo-inflammatory Pathways directly measurable in Urine

10:30AM-12:30PM: Abstract Number: 2410

Immune Cell/Pathway-Specific Polygenic Risk Scores Reveal Immune Pathway Associations in Childhood-Onset Lupus Nephritis

10:30AM-12:30PM: Abstract Number: 2394

Impact of Immunosuppressive Regimens on Major Cardiac Events in Patients with Systemic Lupus Erythematosus (SLE): A Survival Analysis

10:30AM-12:30PM: Abstract Number: 2393

Improving Clinical Outcomes In SLE Arthritis Trials: Post-Hoc Analysis Of A Prospective Intervention Study

10:30AM-12:30PM: Abstract Number: 2420

In-patient Outcomes of Diabetic Ketoacidosis and Hyperglycemic Hyperosmolar Syndrome in SLE: US National Inpatient Database (2021-2022)

10:30AM-12:30PM: Abstract Number: 2427

Kidney-Specific Four-Protein Index Outperforms Conventional Measures for Detecting Early Kidney Damage in Lupus Nephritis and Diabetic Kidney Disease

10:30AM-12:30PM: Abstract Number: 2387

Lupus Damage Index Revision – Item Generation and Reduction Phases

10:30AM-12:30PM: Abstract Number: 2405

Machine Learning in SLE Diagnosis: Performance of the SLE Risk Probability Index Questionnaire in a Multicenter Cohort of Patients with Systemic Lupus Erythematosus

10:30AM-12:30PM: Abstract Number: 2406

Machine Learning-Based Artificial Intelligence in Systemic Lupus Erythematosus: A Systematic Review of Outcome Prediction and Patient Stratification

10:30AM-12:30PM: Abstract Number: 2407

Mapping Neurological Involvement, Regional Disparities, and Moderators of the Central Nervous System in Adult-Onset Systemic Lupus Erythematosus: A Global Systematic Review and Meta-Analysis

10:30AM-12:30PM: Abstract Number: 2429

mHealth-enabled Peer Coaching for Fatigue in Systemic Lupus Erythematosus (SLE): Preliminary Results from the Restore Energy, Activity Can Help (REACH) Pilot Randomized Controlled Trial

10:30AM-12:30PM: Abstract Number: 2425

Neutrophil Transcriptomics in SLE: Exploring Intrinsic, Ex Vivo Adaptation, and CAR-T Cell Therapy-Induced Changes

10:30AM-12:30PM: Abstract Number: 2418

ORF1p Expression Correlates with STING Activation and IFN Signatures in SLE Nonlesional Skin

10:30AM-12:30PM: Abstract Number: 2384

Patient-Reported Quality of Life in SLE: Association with Biomarker-Derived Disease Activity Index (L-DAI) and hSLEDAI in a Prospective Cohort

10:30AM-12:30PM: Abstract Number: 2426

Physical Activity Patterns and Health-Related Quality of Life in Middle-Aged and Older Adults with Systemic Lupus Erythematosus

10:30AM-12:30PM: Abstract Number: 2379

Predicting Type 1 and Type 2 SLE Activity Using the LupusPRO

10:30AM-12:30PM: Abstract Number: 2436

Preload deficiency as a treatable cause of fatigue and exercise intolerance in SLE

10:30AM-12:30PM: Abstract Number: 2400

Prevalence and Predictors of Types and Subtypes of Pulmonary Diseases in Systemic Lupus Erythematosus: A Population-Based Cross-Sectional Study Using High-Resolution Computed Tomography Scan and Pulmonary Function Testing

10:30AM-12:30PM: Abstract Number: 2435

Relevant Symptoms and Signs of Active Discoid and/or Subacute Cutaneous Lupus Erythematosus Among Participants in a Phase 2 Clinical Trial: Patient-Embedded Qualitative Interviews

10:30AM-12:30PM: Abstract Number: 2381

Renal Tubular Complement C9 Deposition is Linked to Tubulointerstitial Fibrosis and Progression to Chronic Kidney Disease in Lupus Nephritis

10:30AM-12:30PM: Abstract Number: 2390

SLE Genetic Risk Loci in the Context of Environmental Exposure: A Gene-Based Classification and Clinical Insight

10:30AM-12:30PM: Abstract Number: 2434

Specificity of Cell-bound T Cell Biomarkers (TC4d, TIgG, TIgM) in Differentiating SLE from ANA-Associated Rheumatic Diseases

10:30AM-12:30PM: Abstract Number: 2377

Statin Use for Primary Prevention of Atherosclerotic Cardiovascular Disease Among Patients with Systemic Lupus Erythematosus

10:30AM-12:30PM: Abstract Number: 2411

The 2019 EULAR/ACR and 2012 SLICC Classification Criteria for SLE Should Be Applied with Caution as Diagnostic Criteria

10:30AM-12:30PM: Abstract Number: 2383

The Age-Adjusted Charlson Comorbidity Index (CCI) Predicts All-Cause Mortality in Systemic Lupus Erythematosus (SLE) Patients: Data from the Almenara Lupus Cohort

10:30AM-12:30PM: Abstract Number: 2433

The Clinical Utility of a Multianalyte Lupus Risk Score Incorporating Cell-bound Complement Activation Products: A Systematic Evaluation

10:30AM-12:30PM: Abstract Number: 2385

The Presence of Avascular Necrosis in Patients with Systemic Lupus Erythematosus Undergoing Total Knee Arthroplasty is Not Associated with Worse Outcomes

10:30AM-12:30PM: Abstract Number: 2421

Whole Blood Immune Phenotyping Reveals Cytometric Differences in B Cell Clusters Between Lupus Nephritis and Non-Lupus Nephritis SLE Patients with Minimal Proteinuria

« View all sessions from this meeting

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].